Targeted activation of androgen receptor signaling in the periosteum improves bone fracture repair

Kuo-Chung Lan1,2,7, Kuo-Ting Wei1,2,7, Pei-Wen Lin1,2, Ching-Chen Lin3, Pei-Ling Won1, Ya-Fen Liu1,2, Yun-Ju Chen1,2, Bi-Hua Cheng1,2, Tien-Min G. Chu4, Jia-Feng Chen2,5, Ko-En Huang1, Chawnshang Chang6 and Hong-Yo Kang1,2✉

© The Author(s) 2022

Low testosterone level is an independent predictor of osteoporotic fracture in elderly men as well as increased fracture risk in men undergoing androgen deprivation. Androgens and androgen receptor (AR) actions are essential for bone development and homeostasis but their linkage to fracture repair remains unclear. Here we found that AR is highly expressed in the periosteum cells and is co-localized with a mesenchymal progenitor cell marker, paired-related homeobox protein 1 (Prrx1), during bone fracture repair. Mice lacking the AR gene in the periosteum expressing Prrx1-cre (AR-/-;Prrx1::Cre) but not in the chondrocytes (AR-/-;Col-2::Cre) exhibits reduced callus size and new bone volume. Gene expression data analysis revealed that the expression of several collagens, integrins and cell adhesion molecules were downregulated in periosteum-derived progenitor cells (PDCs) from AR-/-;Prrx1::Cre mice. Mechanistically, androgens-AR signaling activates the AR/ARA55/FAK complex and induces the collagen-integrin α2β1 gene expression that is required for promoting the AR-mediated PDCs migration. Using mouse cortical-defect and femoral graft transplantation models, we proved that elimination of AR in periosteum of host mice impairs fracture healing, regardless of AR existence of transplanted donor graft. While testostereon implanted scaffolds failed to complete callus bridging across the fracture gap in AR-/-;Prrx1::Cre mice, cell-based transplantation using DPCs re-expressing AR could lead to rescue bone repair. In conclusion, targeting androgen/AR axis in the periosteum may provide a novel therapy approach to improve fracture healing.

Cell Death and Disease (2022)13:123 ; https://doi.org/10.1038/s41419-022-04595-1

INTRODUCTION

Bone repair after fracture is a complex process in which the periosteum is stimulated to form a cartilaginous callus, which subsequently undergoes bone regeneration [1]. Removal or damage of the periosteum dramatically delays the healing of bone fractures [2]. Periosteal cells are a major source of soft callus in bone fracture [3], and a large proportion of cartilage and woven bone in the early fracture callus is derived from the periosteum adjacent to the fracture site [4]. The periosteum plays a key role in the repair and regeneration of fractures through the activation of multipotent periosteum-derived progenitor cells (PDCs) [5, 6]. Understanding how PDCs are activated, recruited, and migrate to the injury site, provides insight into the underlying mechanisms and is important for identifying approaches for improving fracture repair outcomes.

Androgens—sex steroids that are well documented to act as anabolic hormones in males—exert effects on skeletal development and homeostasis [7, 8]. Androgens act mainly through binding to the androgen receptor (AR), which functions as a ligand-inducible transcription factor that controls an integrated gene-expression program and nongenotropic signaling required for bone health and disease [9–11]. Men with complete androgen insensitivity syndrome owing to loss of function mutations in AR gene have diminished vertebral and femoral bone density [12], supporting a seminal role for the AR in the accrual and/or maintenance of bone density. Furthermore, androgens are critical for increased periosteal bone formation during puberty and aging in men [13], likely accounting for the lower incidence of spine fractures in men than women [14–16]. Notable in this context, a low serum level of free testosterone is an independent predictor of bone mineral density (BMD) and the risk of osteoporotic fracture in elderly men [17–19]. The data from observational studies with over 50,000 participants found that androgen deprivation therapy either through gonadotropin-releasing hormone agonist or orchiectomy increased the relative risk of fracture by 1.54 and 1.45, respectively [19–21], suggesting deficiency of androgen-AR signaling pathway increased fracture risk in men undergoing androgen deprivation.

Using genetically modified mouse models for targeted disruption of AR gene, we and others have shown that AR is essential for bone mineralization [22, 23] and deficiency of AR signaling in bone marrow mesenchymal stem/progenitor cells (MSCs) leads to
increased adipogenesis, decreased osteogenic differentiation, and subsequent age-related bone loss [24, 25]. While male mice with targeted deletion of AR gene in osteoprogenitors [26], mature osteoblasts [27] or osteocytes [28] only have lower cancellous bone mass, but no the cortical phenotype, the role for AR in cortical fracture repair remains to be determined. Here, we sought to investigate whether the actions of androgen/AR signaling in PDCs are required for fracture repair.

RESULTS
AR in the periosteum is required for regulation of callus volume and new bone formation during fracture healing
To study where the functional roles for AR signaling execute during fracture repair, we first analyzed the expression of the AR in the fracture callus by immunohistochemical staining. The results revealed that on days 3–7 post fracture, expression of the AR became evident in the periosteum, reaching a maximum on day 10 post fracture in the osteochondro progenitor cells of the inner cambium layer but not in the calcified chondrocytes from the cartilage of fracture callus (Fig. 1A). Paired-related homeobox protein 1 (Prx1) has been detected in osteochondro progenitor cells in the periosteum at the fracture site as a periosteal marker [29]. Our immunoﬂuorescence staining further showed the colocalized expression of the AR and Prx1 in periosteal cells overlying the fracture callus at 10 days after fracture (Fig. 1B).

To further clarify the potential of the periosteum as a source of cells for AR-mediated bone repair, we then established Prx1-specific ARKO (AR−/−Prx1−/−Cre-Rosa26-LacZ) mice. Expression of the Rosa26-LacZ reporter allele represents the Cre recombinase activity on the deletion of AR gene was further analyzed by X-gal staining in a model of femoral fracture. The presence of X-gal-positive cells revealed where recombination was observed in cells of the periosteum, undifferentiated cells at the fracture site and chondrocytes in the cartilaginous callus of Prx1-specific ARKO mice but not control mice (Fig. 1C).

To dissect the actions of AR signaling in a range of cell types that contribute to the process of fracture healing, we generated genetically engineered mice in which the AR gene was specifically ablated in periosteal cells (AR−/−Prx1−/−Cre mice) or chondrocytes (AR−/−Col2α−/−Cre mice), and created a closed transverse femoral fracture to compare the bone healing with that in ARloxPlox mice. As shown in the three-dimensional (3D) micro-computed tomography (micro-CT) images and quantitative analyses, fracture healing was delayed in AR−/−Prx1−/−Cre mice, but not in AR−/−Col2α−/−Cre mice, compared with ARloxPlox mice (Fig. 2A). Total callus volume (TV) (Fig. 2B) and new bone volume (BV) (Fig. 2C) in the fracture callus were significantly decreased in AR−/−Prx1−/−Cre mice compared with ARloxPlox mice on days 14–42 post fracture. A mix of bone, cartilage, and fibrotic tissue filled 21-day fracture calluses, as demonstrated using Acanthia Blue/Hematoxylin (cartilage in blue color) and Goldner trichome (bone in green color) staining (Fig. 2D). Quantitative histomorphometric analyses revealed that a lower percentage of new bone formation but a higher proportion of cartilage and fibrotic tissue were exhibited in the callus of AR−/−Prx1−/−Cre mice than ARloxPlox and AR−/−Col2α−/−Cre mice (Fig. 2E).

AR signaling may play positive roles to increases osteogenic differentiation of PDCs in vitro
To elucidate the molecular pathways by which AR signaling regulates activation of periosteal PDCs during fracture repair, we first isolated and characterized PDCs derived from the callus periosteum of 9- to 11-day-old ARloxPlox mice. As shown in Supplementary Fig. 1A, these isolated cells expressed several well-known markers for MSCs such as Sca-1, CD29, CD105 and CD140, but not the hematopoietic cell markers, CD11b, CD34 and CD45 similar to mouse D1 bonestromal precursor cells (Supplementary Fig. 1A). Using a Rosa-Cre mouse model that allows efficient deletion of the AR gene, we were able to isolate PDCs from both ARloxPlox and AR−/−Prx1−/−Cre mice. In contrast to the expression pattern that of the TM4 Sertoli cell line, these Rosa-positive PDCs expressed periostin, a key regulator of periosteal cells with high bone regenerative potential in the periosteum and their stem cell niche [30], as well as Prx1, fibroblast growth factor receptor 3 and fibroblast growth factor 18, markers of periosteal cells to coordinate chondrogenesis and osteogenesis [29], suggesting that these PDCs have the osteochondrogenic potential (Supplementary Fig. 1B). To determine the multiple lineage differentiation capacity of these cells in vitro, we treated the cells with lineage-specific differentiation media and found that these cells are capable of differentiating into osteoblasts, adipocytes and chondrocytes, establishing the multipotency of these PDCs (Supplementary Fig. 1C, D). To determine whether AR signaling has osteogenesis-promoting effects on these PDCs, we cultured AR-overexpressing PDCs in osteogenic medium and measured cell mineralization by Von Kossa staining. As shown in Supplementary Fig. 1E, calcium deposition and expression of the small integrin-binding ligand N-linked glycoprotein gene family members including bone sialoprotein, matrix extracellular phosphoglycoprotein, and dentin matrix acidic phosphoprotein 1, which are important in AR-mediated matrix mineralization [22], were increased in PDCs stably overexpressing a constitutively active AR.

Identification of AR downstream genes during bone fracture repair
Next, a microarray analysis was used to identify specific genes that were differentially expressed in PDCs isolated from ARloxPlox and AR−/−Prx1−/−Cre mice, particularly those with a role in bone fracture repair. Genes involved in the bone fracture repair processes, including those encoding extracellular matrix (ECM) proteins and cell adhesion molecules, as well as proteins that influence skeletal development, bone mineral metabolism, cell growth and differentiation, were selected (Supplementary Table 1). Notably, among the downregulated genes in PDCs isolated from ARloxPlox mice (Supplementary Fig. 1), many members of the collagen family, including Col1α1, Col1α2, Col2α1, Col6α1, Col7α2, Col11α1 and Col12α1, which have previously been described as important ECM proteins in fracture repair models [31, 32]. In addition, genes involved in cell–cell adhesion and cell-matrix adhesion, such as the integrins, Itga2, Itgb2, Itgb1 and Itga3, also exhibited an overall reduction in expression in PDCs isolated from ARloxPlox mice compared with ARloxPlox mice (Supplementary Table 1). Results from the RT-qPCR assay confirmed that mRNA levels of AR, Itga1, Itga2, Itga3, Col6α1, Col7α2, Col11α1, Col12α1, Itga2 and Itgb1 were decreased in primary PDCs from ARloxPloxPrx1−/−Cre mice (Supplementary Fig. 2).

Collagens-integrins signaling is essential for AR to increase the cell migration and adhesion in PDCs
Integrins are collagens-binding receptors expressed in bone and cartilage tissues, and serve bridges for cell-matrix interactions during bone fracture repair [33–35]. We first applied the RT-qPCR assay to confirm that expression of the integrin genes, Itga2 (encoding integrin α2) and Itgb1 (encoding integrin β1), identified by our microarray, were suppressed in both ARloxPloxPrx1−/−Cre PDCs and AR-knockdown ARloxPlox PDCs, whereas re-expression of the AR increased Itgb1 and Itga2 mRNA levels in D1 cells (Fig. 3A, B).

The mobilization of adult skeletal stem cells/progenitors to allow deposition of cartilage and formation of bone at the injury site are key in promoting fracture repair [6]. Accordingly, we further studied the impact of AR signaling in the migration of primary PDCs and the mouse D1 bone marrow stromal precursor cell line. Results from a cell-migration analysis revealed that migration of primary PDCs from ARloxPloxPrx1−/−Cre mice was decreased compared with that of PDCs from ARloxPlox mice (Fig. 3C, left panel). Similar
Fig. 1  The AR is expressed in the periosteum during the fracture healing process. A  Histological sections of post-fracture calluses at 3, 7, 10, 14, 21 and 28 days were analyzed by Safranin O/Fast Green staining and immunohistochemical analysis of AR expression. Scale bar = 100 µm. B Double-immunofluorescence staining revealed co-localization of the AR (red) and Prx1 (green) in the periosteum of post-fracture calluses at 10 days. Scale bar = 50 µm. C X-gal-stained cells were observed in the post-fracture callus at 10 days in AR<sup>flox/lox</sup>Prx1:Cre::Rosa26-LacZ mice (right panel); and AR<sup>flox/lox</sup> mice (left panel) were used as negative controls. Scale bar = 50 µm. a. periosteum; b. mesenchyme; c. chondrocytes. Scale bar = 100 µm.
results were obtained when AR was knocked down by small interfering RNA (siRNA) in PDCs from AR\textsuperscript{fl ox/Y} mice, showing cell migration was also significantly decreased compared with cells transfected with control (scrambled) siRNA (Fig. 3D, left panel). In contrast, increase AR via adding AR-cDNA in D1 cells led to increase cell migration compared with control cells transfected with empty vector (Fig. 3E, F, left panel). These results were further confirmed by adding dihydrotestosterone (DHT) that led to an increase in the AR expression as well as the cell adhesion affinity and migration in a concentration-dependent manner, and these increased effects were reversed/blockaded after adding antiandrogen hydroxyflutamide (Supplementary Fig. 3A–C). Similar results were also obtained when we replaced androgen/antiandrogen with AR-cDNA/AR-siRNA in D1 cells, showing cell adhesion and migration were positively regulated by androgen/AR (Supplementary Fig. 3D, E).

We then examined the impacts of the αβ1 integrin, a major receptor for collagen I, on AR- promoted cell migration. Adding collagen I led to increasing cell migration compared with control cells transfected with empty vector (Fig. 3E, F, left panel). These results were further confirmed by adding androgenic osteoblasts (DHT) that led to an increase in the AR expression as well as the cell adhesion affinity and migration in a concentration-dependent manner, and these increased effects were reversed/blockaded after adding antiandrogen hydroxyflutamide (Supplementary Fig. 3A–C). Similar results were also obtained when we replaced androgen/antiandrogen with AR-cDNA/AR-siRNA in D1 cells, showing cell adhesion and migration were positively regulated by androgen/AR (Supplementary Fig. 3D, E).

We then examined the impacts of the αβ1 integrin, a major receptor for collagen I, on AR- promoted cell migration. Adding collagen I led to increasing cell migration compared with control cells transfected with empty vector (Fig. 3E, F, left panel). These results were further confirmed by adding androgenic osteoblasts (DHT) that led to an increase in the AR expression as well as the cell adhesion affinity and migration in a concentration-dependent manner, and these increased effects were reversed/blockaded after adding antiandrogen hydroxyflutamide (Supplementary Fig. 3A–C). Similar results were also obtained when we replaced androgen/antiandrogen with AR-cDNA/AR-siRNA in D1 cells, showing cell adhesion and migration were positively regulated by androgen/AR (Supplementary Fig. 3D, E).

AR/ARA55/FAK complex is required for the FAK activation to increase the androgen-mediated cell migration in D1 cells

Integrins couple the ECM to the cytoskeleton through the formation of cell adhesion complexes by regulation of the FAK-Hic-5/ARA55 axis during the cell migration [36]. To further study if nongenotropic AR signaling may function via activating the FAK-ARA55 function to increase cell adhesion and migration, we first used an immunoprecipitation approach to isolate the AR-interacting proteins, and we examined the recruitment of FAK and ARA55 to the AR protein complex upon DHT treatment. Whole-cell extract analysis revealed that DHT led to an increase in the protein expression of AR but not FAK or ARA55 (Fig. 4A, bottom panel). Immunoprecipitation assay demonstrated that the formation of AR/ARA55/FAK complexes is not DHT-dependent (Fig.4A, upper panel), and the interaction between AR and FAK was diminished via adding AR-siRNA (Fig. 4B, upper panel). Similar results were also obtained when we isolated and analyzed the FAK protein complex (Fig. 4A, B, middle panel).

Since changes in the cytoskeleton architecture and tyrosine phosphorylation of FAK proteins at focal contact sites are hallmarks of migrating cells [37], we then analyzed the effect of androgens-AR on tyrosine phosphorylation of FAK. DHT treatment for 15 or 60 min resulted in increasing the phosphorylation of FAK at Tyr-397 (Fig. 4C) and overexpressing AR led to an increase in the tyrosine phosphorylation of FAK (Fig. 4D). When FAK was knocked down by FAK-siRNA in D1 cells, AR-promoted cell migration was significantly decreased compared with cells transfected with control (scrambled) siRNA (Fig. 4E).
Using a live segmental defect and bone graft transplantation models to prove delivery of testosterone and AR-expressing PDCs enhances bone repair

To dissect the role of AR in the initiation of periosteal healing, we first utilized a murine femoral graft transplantation model, in which live segmental grafts from the same strains were transplanted and donor versus host cell involvement in healing was assessed. Micro-CT 3D reconstructions and quantitative analyses demonstrated abundant new bone formation along with the increasing callus volume of the graft in AR<sup>flox/Y</sup>-to-AR<sup>flox/Y</sup>...
transplantations, whereas new BV and callus volume was significantly reduced in AR–/–;Prrx1::Cre-to-AR–/–;Prrx1::Cre grafts compared to ARflow/Y to ARflow/Y transplantation. When ARflow/Y donor graft was transplanted into an AR–/–;Prrx1::Cre host mouse, a similar reduction of bone and callus formation was observed. In contrast, transplantation of AR–/–;Prrx1::Cre graft into ARflow/Y host mice resulted in the marked recovery of new bone and callus formation on both host bone and donor graft, suggesting that AR deficient donor cells were capable to form new bone when placed in ARflow/Y host mice. (Fig. 5A, B).

Quantitative histomorphometric analyses showed that ARflow/Y to ARflow/Y transplantation resulted in normal endochondral bone healing with induction of periosteal bone and cartilage formation in the callus. In contrast, transplantation of AR–/–;Prrx1::Cre graft into AR–/–;Prrx1::Cre host mice led to a significant reduction of bone formation and the callus was occupied by the predominant proportion of fibrotic tissues but no cartilage formation. When an AR–/–;Prrx1::Cre graft was transplanted into ARflow/Y host mice, periosteal cell-initiated endochondral bone formation was not significantly altered. In contrast, transplantation of ARflow/Y graft into an AR–/–;Prrx1::Cre host mouse resulted in the reduction of bone formation and a large amount of fibrotic tissues were found at the cortical junctions and along bone graft surface, similar to AR–/–; Prrx1::Cre-to-AR–/–;Prrx1::Cre transplantation, indicating that deletion of AR in Prrx1::Cre expressing cells from host mice impaired the function of ARflow/Y donor graft (Fig. 5C, D).

To investigate whether AR signaling in PDCs promotes bone fracture healing, we isolated primary PDCs from ARflow/Y or AR–/–; Prrx1::Cre mice. These donor PDCs were then injected via the tail vein into ARflow/Y host mice with stable closed fracture, and TV and new BV were analyzed by micro-CT analysis during fracture repair (Supplementary Fig. 4A). The results revealed that PDCs derived from AR–/–;Prrx1::Cre mice resulted in a significantly reduced amount of callus and bone with retaining a large port of unmineralized cartilages compared with ARflow/Y mice-derived PDCs (Supplementary Fig. 4B–E). In contrast, re-expressing AR in PDCs derived from AR–/–; Prrx1::Cre mice increased the TV and new trabecular bone formation (Supplementary Fig. 4B–E). To further evaluate potential strategies for experimental treatments in a segmental bone defects model, we created a 2.5-mm-wide osteotomy and implanted testosteRone scaffolds in ARflow/Y and AR–/–;Prrx1::Cre mice in combination with or without injection of PDCs (Fig. 6A). The results from Micro-CT 3D reconstructions and quantitative analysis showed that implanted scaffolds containing testosteRone increased TV, new bone formation and completed callus bridging across the fracture gap in ARflow/Y mice, but not in AR–/–;Prrx1::Cre mice (Fig. 6B–E), suggesting that AR is required for testosteRone therapy to enhance callus volume and new bone formation. Notably, injected PDCs from ARflow/Y mice also increased callus volume and new bone formation not only in both ARflow/Y but also in AR–/–;Prrx1::Cre mice (Fig. 6D, E). However, combination therapy with testosteRone and PDCs formed a solid completed callus bridge (Fig. 6C) and had additional effects on new bone formation and callus volume in ARflow/Y mice but not in AR–/–; Prrx1::Cre mice (Fig. 6D, E).

DISCUSSION

The periosteum contains multipotent PDCs that improve bone regeneration being suitable for mimetic autograft design [38]. In this study, we elucidate the novel genomic and nongenomic AR actions on PDCs to accelerate bone callus formation in mouse femoral defect models via promoting collagen-integrin expression and interaction to activate AR/ARASS5/FAK axis, therefore increasing the transduction of androgen signaling to focal adhesion complex in regulating PDCs migrated to the site of skeletal injury (Fig. 7).

Testosterone accelerates fracture healing in eugonadal male and female mouse models [39] and exerts a direct peripheral effect on the callus cells and stimulates fracture healing [40]. Androgens stimulate periosteal bone formation in both men and male rodents [41, 42] and are known to have a direct effect on bone healing, as it induced callus formation in segmental bone defect mouse models [43], which are in line with our present results that male mice lacking AR (AR–/–;Prrx1::Cre) have decreased periosteal cell activity with low levels of collagens and integrins and testosterone can only promote bone fracture repair in ARflow/Y control mice, but not in AR–/–;Prrx1::Cre mice. Together, these data suggest androgen/AR activation in the cells of periosteum is required for the development of trabecular bone and periosteal bone formation in the calluses during endochondral ossification of bone repair.

The ECM serves as a reservoir for hormones, growth factors, and cytokines that regulate cellular activation and behavior. The main constituent of the ECM in bone is type I collagen [44]. Cell adhesion to extracellular collagens is mediated by a subset of integrins, which have a special collagen-binding domain [33, 45, 46]. Members of the β1 subfamily of integrins are reported to be the most highly expressed integrins and the predominant mediators of cell adhesion in osteoprogenitors and osteoblasts [47, 48]. Several studies have indicated that the interaction of α2β1 integrin with collagen I is a crucial signal for osteoblastic differentiation and matrix mineralization [49–52]. Integrins have been shown to express in many mesenchymal cells and are required for homing stem progenitor cells to fracture sites for bone repair [53]. Diminished callus size and cartilage synthesis was observed in α1β1 integrin-deficient mice during bone fracture healing [34]. The downstream signaling of ECM–integrin interations is governed by FAK activation, which leads to induction of the mitogen-activated protein kinases ERK1/2 and PI3K–Akt signaling in osteoblasts [48]. Interaction between integrin and collagen I activates FAK, which is involved in osteoblastic differentiation and matrix mineralization [52, 54, 55]. Previous reports have shown that FAK activation through phosphorylation of Tyr-397 is critical for osteoblast adhesion and migration, as well as bone formation in fracture healing [56–58]. During the differentiation process, FAK is continuously activated from MSCs to osteoblasts [59, 60]. A FAK deficiency in osteoblasts and osteocytes in vivo results in delayed bone healing and remodeling [61, 62]. ARASS5 is a homologous focal adhesion adaptor protein that coordinates cytoskeletal rearrangements in response to integrin signaling in focal adhesion. ARASS5 also acts as an AR coregulator [63] to regulate AR target genes, affected androgen-mediated cell mobility [64]. It is possible
that androgen/AR signaling first acquires ARA55 as a transcriptional coactivator to increase the expression of various collagens and their receptors to maintain the balance of ECM–integrin interactions, which may then activate the FAK via increasing the formation of focal adhesion complex to promote the migration of PDCs.

Bone autografting is the most effective grafting application [65], because such grafts contain bone-forming stem cells and proteins in the periosteum, which provide a framework and microenvironment for new bone growth during fracture healing. Removal of the periosteum from bone grafts dramatically decreased neovascularization and new bone and cartilage formation, leading to
poor bone healing [4, 66]. Our current study showed that bone graft healing was more efficient in AR$^{flox/Y}$ but not AR$^{-/Y}$ host mice regardless of implanting with either AR$^{flox/Y}$ or AR$^{-/Y}$;Prrx1::Cre donor bone, suggesting that AR may orchestrate crucial healing signaling for activation and differentiation of periosteal progenitors in host mice and elimination of AR in periosteum of host mice at the early stage of fracture healing could lead to detrimental effects on periosteum-initiated cortical bone repair. Another notable outcome of our study was the success of bone regeneration by transplanted AR-expressing PDCs in a mouse femoral defect reconstruction model, illustrating the remarkable ability of AR-expressing PDCs to promote bone regeneration as an emerging concept in fracture therapy. However, how androgen signals dictate the cells from the periosteal progenitor lineage to be recruited and enriched to the injury sites of bone fracture, and whether androgen/AR signaling can activate the paracrine signalings of these cells in bone healing niches, remains to be further elucidated.

Incorporation of growth factors into the scaffold biomaterial to elicit the periosteal response can improve osteogenesis and angiogenesis in the fracture sites [67]. The most notable known signaling molecules are bone morphogenic proteins (BMPs), fibroblast growth factors, platelet-derived growth factor, vascular endothelial growth factor, transforming growth factor-β and insulin-like growth factors, which have positive effects on bone healing [68–71]. Similar to our finding of the temporal and spatial expression of AR during the early phase of fracture healing, BMP-2 and its receptors was also able to induce the interaction of α2β1 integrin with collagen I [50], in the callus on the periosteal surface of the femur just a few days after cortical bone fracture [72] and collaboratively works with testosterone to improve bone healing [43]. It is possible that bone healing was more efficient in AR$^{flox/Y}$ but not AR$^{-/Y}$ mice due to the presence of AR for the activation of BMP-2 and other growth factors signaling to recruit the DPCs which increase bone regeneration. However, detailed studies are needed to determine the crosstalk among BMP-2, other growth factors signaling and androgens/AR-promoted bone healing in the periosteum and whether androgens/AR pathway can be activated to improve the allograft efficiency in clinical fracture therapy.

In conclusion, we demonstrated that AR in DPCs is a positive regulator of bone repair, suggesting that androgen-treated PDCs represent a novel potential clinical implement for bone formation and regeneration. Therapeutic efficacy and reliability are two major advantages of bone graft implantation in repairing bone defects. If the very encouraging outcomes via increasing androgen/AR axis in the periosteum prove to be reproducible in mammals, it may pave the way for the development of clinical applications.

METHODS

Animals

Detailed procedures for the generation of floxed AR mice and genotyping are described in our previous paper [73]. The strains of mosaic founder mice were C57BL/6 and 129Sv and backcrossed to C57BL/6J for 12 generations. Prx1-Cre (Prx1::Cre) (Stock 005840), Col-2-Cre (Col-2::Cre)
Bone scaffolds
Scaffolds were produced as described previously [74]. Briefly, a thermal-curable polypropylene fumarate (PPF)/tricalcium phosphate (TCP) suspension was prepared by mixing PPF, N-vinyl pyrrolidinone, and TCP at a weight ratio of 1:0.75:0.66. The PPF/TCP slurry was then mixed with 0.5% benzoyl peroxide (thermal initiator) and 10 ml of dimethyl p-toluidine (accelerator), and cast into a wax mold to produce tube-shaped structures (outer diameter, 2 mm, inner diameter 0.6 mm, height 2.5 mm) with two 0.4 mm diameter side holes. These scaffolds were load bearing, as they allowed mobility of fractured bone when applied [74]. In this study, AR flox/Y and AR knockout (AR -/-;Prrx1::Cre) are required 14 days after the operation.

Stable closed femoral fracture model
Eight-week-old mice were anesthetized with xylazine (10 mg/kg) and ketamine (80 mg/kg). An incision in the skin and underlying soft tissues lateral to the patellar tendon was made, and the tendon was displaced medially, after which a small hole was drilled into the distal femur using a 25-gauge needle. A stylus pin from a 25-gauge Quincke Type spinal needle was inserted into the intramedullary canal and clipped, after which the wound was sutured. Fractures were created by using a three-point bending design. Mice were given buprenorphine (0.1 mg/kg) for pain relief for 7 consecutive days, and then were returned to their home cages and allowed to move freely.

Micro-CT and radiography
After the closure of the surgical wound in each mouse with a segmental defect, the left femur with a scaffold of each mouse at days 7, 14, 21, 28, and 42 was scanned to quantitate callus formation by micro-CT (Skyscan 1076). The right femur without scaffold was similarly examined to serve as a control. The scanned images were developed using an X-ray tube voltage of 45 kV and current 100 μA with a 0.5-mm aluminum filter. X-ray image slices were reconstructed using the NRecon (v.1.4.4; Skyscan) software system and the 3D micro-CT images and parameters of bone micro-architecture were calculated using CTAn (v.1.7.0.0; Skyscan) and CTVol.

Fig. 6 Combination of androgen therapy with the DPCs cell-based transplantation augments the repair of segmental bone defects. AR flox/Y and AR -/-;Prrx1::Cre host mice received transplantations of bone grafts from AR flox/Y or AR -/-;Prrx1::Cre donor mice and samples were acquired on 14 days after the operation. A AR flox/Y and AR -/-;Prrx1::Cre mice received segmental bone defects, and then were implanted with scaffold containing vehicle control or 100 μg testosterone. These host mice were also treated with PDCs from AR flox/Y donor mice by tail vein injection. B 3D micro-CT images of defect sites are shown at 35 days post operation. C The percentages of no callus formation, partial callus formation and complete callus bridging across the gap were quantified by X-ray image analysis. D, E The new bone volume and total callus volume were quantified by micro-CT analysis. Data are presented as mean ± SEM (n ≥ 3; *P < 0.05, **P < 0.001, one-way ANOVA). ND not detected.

Fig. 7 Novel androgen-AR-targeted approaches that promote homing of PDCs to bone formation and repair. The targeted androgens-AR and collagen-integrin α2β1 in PDCs can increase the formation of AR/ARASS/FAK complex that resulted promote the PDCs migration via activation of signaling mediated by ECM-integrin interactions, an effect that translates into increased periosteal bone formation and improved bone fracture repair. AR androgen receptor, ARASS AR-associated protein 55, FAK focal adhesion kinase, ECM extracellular matrix, PDCs periosteum-derived progenitor cells.

(Stock 003554) were purchased from The Jackson Laboratory. Eight-week-old male AR flox/Y and AR knockout (AR -/-;Prrx1::Cre and AR -/-;Col-2::Cre) mice were used in this study. All mice were maintained on a C57BL/6 background throughout the study.
(v.1.11.0.1; SkyScan) software. The parameters measured 3D reconstruction and quantitative analyses included the percentage of new BV and TV; trabecular thickness, number, and separation; structure model index; cortical BMD, thickness, and degree of anisotropy were analyzed for each femur according to our previous study [43].

**Femoral bone graft transplantsations**

Eight-week-old AR<sup>flox</sup> and AR<sup>flox</sup>;Prrx1::Cre host mice were anesthetized with xylazine (10 mg/kg) and ketamine (80 mg/kg). A 7–8-mm-long incision was made and the midshaft femur was exposed through blunt dissecting muscles without disturbing the periosteum. The 4-mm mid-diaphyseal backbone segment was removed from the femur of the host mice by cutting the bone using a saw bone. A 4-mm cortical bone mid graft of donor mice was carefully dissected to remove the muscles without compromising the periosteum and then inserted into the host mice with the same size of the segmental defect. The bone graft was stabilized by a 25-gauge stainless steel needle placed through intramedullary marrow cavity. Four groups of bone grafting were performed: AR<sup>flox</sup> donor to AR<sup>flox</sup> host (WT-to-WT), AR<sup>flox</sup>;Prrx1::Cre donor to AR<sup>flox</sup>;Prrx1::Cre host (KO-to-KO), AR<sup>flox</sup> donor to AR<sup>fl</sup> host (WT-to-KO), and AR<sup>flox</sup>;Prrx1::Cre donor to AR<sup>fl</sup> host (WT-to-WT). The grafted femurs were processed for histological and micro-CT analyses at the end time points of the experiments.

**Histological and histomorphometric analysis**

The grafted femurs were harvested, fixed in 10% neutral buffered formalin (Sigma-Aldrich), decalcified in 10% EDTA (Sigma-Aldrich) for histological analyses, tissues were fixed in 4% formaldehyde (Sigma-Aldrich) in PBS overnight. Postnatal tissues were decalcified in Surgipath Decalifier II (Leica Biosystems), then embedded in paraffin. Sections were cut to a thickness of 5 μm, deparaffinized, dehydrated, rehydrated with a graded ethanol series, and stained with Alcian Blue (Sigma-Aldrich)/Hematoxylin G (Sigma-Aldrich) stain and Safranin O (Sigma-Aldrich)/Fast Green (Sigma-Aldrich) dye and Goldner Trichrome (EMS 26386) as previously described [75]. Histomorphometric analyses were performed as previously described [76]. By using Osteometrics<sup>®</sup> software, the area of bone, cartilage and fibrotic tissue formation on the host and graft side were determined. A hypothetical line was drawn in the middle of the distal or proximal junction between the graft and host bone to separate the callus into the graft side callus and the host side callus. Areas of bone, cartilage and fibrotic tissue were traced in a computer program and percent area was used for analyses. At least three non-consecutive sections were used for histomorphometric analyses and a mean of three represents one sample. At least eight samples were included in each group of transplantation. The mean from eight samples was used in statistical analyses to determine the composition of the callus on the host site and graft side.

**Immunohistochemistry, immunofluorescence and X-gal staining**

For immunohistochemistry, sections (5-μm thick) were dewaxed, rehydrated using a graded ethanol series, and subjected to antigen retrieval. Thereafter, sections were first incubated overnight at 4 °C with rabbit polyclonal anti-mouse AR primary antibody (Santa Cruz; sc-7305), diluted 1:100, and then with horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (Dako: K5007). Sections were then incubated with DAB substrate (Dako), dehydrated, and coverslip-mounted. For immunofluorescence, sections (5-μm thick) were incubated with 5% horse serum for 30 min to block unspecified antibody binding, then incubated overnight at 4 °C in a mixture of anti-AR (Santa Cruz; sc-7305) and anti-Prrx1 (Santa Cruz; sc-29968) antibodies, diluted 1:100 in 1% horse serum/TBST (Tris-buffered saline containing 0.1% Tween-20). Thereafter, sections were incubated for 2 h at room temperature in the dark with Texas Red (eBioscience 14:1401-82) CD11b (eBioscience 12:0112-81), CD34 conjugated antibodies against Sca-1 (eBioscience 11:5781-81), CD45 (eBioscience 12:1051-82), CD140, (eBioscience 14:1401-82) CD11b (eBioscience 12:0112-81), CD34 (eBioscience 14:0341-81) and CD45 (eBioscience 14:0451-81), followed by flow cytometry using a FACSARia II system (BD Biosciences, San Jose, CA, USA) in the CGMH Core facility. Voltages and gates were set based on unstained periosteum samples from Cre-negative animals.

**Fluorescence-activated cell sorting (FACS) analyses**

Cell surface markers analysis was performed using phycoerythrin-conjugated antibodies against Sca-1 (eBioscience 11:5781-81), CD29 (eBioscience 12:0291-81), CD105 (eBioscience 12:1051-82), CD140, (eBioscience 14:1401-82) CD11b (eBioscience 12:0112-81), CD34 (eBioscience 14:0341-81) and CD45 (eBioscience 14:0451-81), followed by flow cytometry using a FACSARia II system (BD Biosciences, San Jose, CA, USA) in the CGMH Core facility. Voltages and gates were set based on unstained periosteum samples from Cre-negative animals.

**Semi-quantitative and quantitative RT-PCR, and osteogenesis PCR arrays**

Total mRNA was extracted from TMA4, D1, AR<sup>flox</sup> and AR<sup>flox</sup>;Prrx1::Cre PGCs and PDGs using the Trizol reagent (Invitrogen) according to the manufacturer’s instructions. cDNA was reverse transcribed from 2 μg mRNA using a Promega RT-PCR kit. For semi-quantitative analyses, PCR was performed on an Applied Biosystems GeneAmp PCR system Verit 96-well Thermal cycler (27–35 cycles), and band intensities were compared during the linear portion of the amplification cycle. Quantitative PCR was performed on an Applied Biosystems 7500 Real-time PCR detection system using cDNA-specific gene隔离物的用途

细胞死亡和疾病 (2022) 13:123
primers and SYBR green master mix (Applied Biosystems). Gene expression levels were compared using the comparative cycle threshold method, with β-actin as input control.

For osteogenesis, microarray analyses were performed on an Applied Biosystems 7500 Real-time PCR detection system using a mouse osteogenesis PCR array kit (Qiagen). The mouse osteogenesis RT Profiler PCR Array profiles the expression of 84 genes related to osteogenic differentiation. This array contains genes that function in the development of the skeletal system as well as in bone mineral metabolism, and includes growth factors and genes that mediate osteogenesis and related cell growth, proliferation, and differentiation processes. Also represented are ECM molecules and cell adhesion molecules involved in bone development.

Cell migration assay
Primary PDCs were isolated from ARlox/Y and AR -/Y Prx1-Cre mice. The AR in PDCs from ARlox/Y mice was knocked down using AR-targeting siRNA. D1 cells were transfected with Flag or Flag-targeted AR. All cells were cultured in αMEM containing 15% FBS, 100 U/ml penicillin/streptomycin, 2 mM L-glutamine on Oris™ cell migration plates containing cell seeding stoppers. The cells were allowed to attach and spread for 1–20 h prior to manual removal of the stoppers. The cells were washed and then incubated for 30 min in 100 μl of αMEM medium containing 50 μM Cell Tracker Blue (Invitrogen). The cells were washed, and the medium was replaced with αMEM containing 15% FBS, with or without 2 μg collagen I (R&D), 30 nM TC-15 (α2β1 integrin inhibitor; TOCRIS) or 10 μg/ml CD49 antibody (Becton Dickinson). Images were captured on an Acumen explorer using a 488-nm laser and >655-nm filter. A square around the cell-free zone—the migration area—was defined. For siRNA assay, si-integrinB1 #16412, si-FAK #14083-ON-TARGETplus SMARTPool-siRNA from Dharmacon, a rectangle encompassing the confluent cell monolayer from the same well-defined migration region. Cells were gaged using mean intensity measurements. D1 cells (multipotent mouse bone marrow stromal precursor) were transfected with PSGS or PSGS-AR. All cells were cultured in αMEM containing 15% FBS, 100 U/ml penicillin/streptomycin, 2 mM L-glutamine on Millicell Single Well Hanging Inserts cell migration plates (Millipore: PIEP 12R 48) containing cell seeding stoppers. Prepare PSGS, PSGS-AR cell suspension containing 0.5–1.0× 10^6 cells/ml in serum-free media. Add 500 μl of media containing 10% FBS to the lower well of the migration plate. Add 300 μl of cell suspension solution to the inside of each insert. Incubate for 48 h in a cell culture incubator. Carefully aspirate the media from the inside of the insert. Wet the ends of three cotton-tipped swabs and gently swab the interior of the inserts to remove non-migratory cells. Take care not to puncture the polycarbonate membrane. Be sure to remove cells on the inside perimeter of the insert. Transfer the insert to a clean well containing 400 μl of Cell Stain Solution (10% triton x-100) and incubate for 40 min at room temperature. Gently wash the stained inserts several times in a beaker of water. Allow the inserts to air dry. Count migratory cells with a light microscope under a high magnification objective, with at least three individual fields per insert.

Immunoprecipitation
Cells were lysed in lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM Na3VO4, 1 mM NaF, and 1 μg/ml aprotinin). Cell lysates containing an equal amount of protein (1.2 mg) were incubated with 4 μg anti-AR or anti-FAK antibody at 4 °C overnight. Protein–protein interactions were studied by performing immunoprecipitation using a Catch and Release v2.0 reversible immunoprecipitation system (Millipore Corporation), as per the manufacturer’s instructions. Thereafter, proteins in samples were resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE), transferred to PVDF membranes, and immunooblotted with anti-AR (Millipore PG-21 #06-680), anti-ARAS5 (BD Biosciences #61164) or anti-FAK antibody (BD Biosciences #610088).

Immunoblotting
Cell extracts were prepared in lysis buffer (50 mM Tris-HCl pH 6.8, 120 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 1 mM PMSF, 1 mM β-mercaptoethanol, 1 mM Na3VO4, 1 mM NaF, and 1 μg/ml aprotinin) for 30 min on ice, and centrifuged at 15,000 × g for 15 min to remove insoluble materials. Lysates were centrifuged at 14,000 rpm for 10 min, and the resulting supernatants were used for immunoblotting. Protein concentrations were determined using the Pierce protein assay reagent (Pierce, Rockford, IL, USA). Cell lysates containing equal amounts of protein (40 μg) were analyzed by SDS–PAGE. After transferring to Hybond-P membranes and blocking with 5% milk/0.1% TBST at room temperature for 60 min, membranes were incubated first with primary antibodies AR (Millipore PG-21 #06-680), FAK (BD Biosciences #610088), p-FAK(BD Biosciences #611722), ARAS (BD Biosciences #61164), Integrin β1 (Cell Signaling #4706), GAPDH (Millipore #AB23202) overnight at 4 °C, and then with HRP-conjugated anti-mouse or anti-rabbit IgG secondary antibodies. Immunoreactive proteins were detected using an enhanced chemiluminescence detection kit (Millipore). Signals were analyzed and quantified using an LAS-3000 imaging system (Fujiﬁlm, Tokyo, Japan).

Combination therapy of testosterone and PDCs in mice with critical-size segmental defects
Eight-week-old ARlox/Y or AR -/Y male mice were used to generate a segmental defect of approximately 2.5 mm on the left femur of each mouse using a rotating blade with copious irrigation as we previously described [43]. Briefly, a 2.5-mm PPF/TCP scaffold loaded with phosphate-buffered saline (PBS; blank) or 100 μg testosterone (Sigma) was inserted to bridge the fracture. After the fracture, 1 × 10^6 PDCs from ARlox/Y and AR -/Y mice were transplanted into segmental defective mice treated with PBS or testosterone (Sigma). A 25-gauge stainless steel needle was used as an intramedullary pin. The needle was drilled into the trochar groove between the lateral and medial condyles to reach the femur marrow cavity. It was allowed to pass through the central channel of the scaffold and attached to the proximal end of the femur marrow cavity. Mice were given buprenorphine (0.1 mg/kg) for pain relief for 7 consecutive days, and then were returned to their home cages and allowed to move freely.

Statistical analyses
Panels generally represent multiple independent experiments performed on different days with different mice. No blinding experiment or randomization-based analysis was used. Data are presented as mean ± SEM unless otherwise stated. Unpaired, two-tailed Student t tests were used for comparisons between two groups. For multiple comparisons, one-way ANOVA with Dunn’s post hoc test was applied. A P value less than 0.05 was considered significant. Each animal was assigned an identification number using the animal’s litter number in combination with the ear tag number. All data were normally distributed and had similar variations between groups. Data were analyzed by SPSS version 15 or SigmaStat statistics version 4.

Study approval
We maintained all animals in the animal facility of the Chang Gung Memorial Hospital, Kaohsiung, Taiwan. The experimental protocols followed the Guide for the Care and Use of Laboratory Animal of the Institute of Laboratory Animal Resources, National Research Council, National Academy of Sciences, USA, and approved by the Institutional Animal Care and Use Committee of the Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

DATA AVAILABILITY
All data generated or analyzed during this study are included in this published article.

REFERENCES
1. Loi F, Cordova LA, Pajarena J, Lin TH, Yao Z, Goodman SB. Inflammation, fracture and bone repair. Bone. 2016;68:119–30.
2. Evans SF, Chang H, Knothe Tate M.L. Elucidating multiscale periostal mechanobiology: a key to unlocking the smart properties and regenerative capacity of the periostum? Tissue Eng Part B Rev. 2013;19:147–59.
3. Murao H, Yamamoto K, Matsuda S, Akiyama H. Periosteal cells are a major source of soft callus in bone fracture. J Bone Miner Metab. 2013;31:390–8.
4. Zhang X, Awad HA, O’Keefe RJ, Gulberg RE, Schwarz EM. A perspective: engineering periosteum for structural bone graft healing. Clin Orthop Relat Res. 2008;466:1777–87.
5. Colnot C. Skeletal cell fate decisions within periosteum and bone marrow during bone regeneration. J Bone Miner Res. 2009;24:2748–82.
6. Wang X, Wang Y, Guo W, Lu P, Deng J, Lu S. Role of mesenchymal stem cells in bone regeneration and fracture repair: a review. Int Orthop. 2013;37:2491–8.
7. Compston JE. Sex steroids and bone. Physiological Rev. 2001;81:419–47.

K.-C. Lan et al.
8. Almeida M, Laurent MR, Dubois V, Claessens F, O'Brien CA, Bouillon R, et al. Estrogens and androgens in skeletal physiology and pathophysiology. Physiological Rev. 2017;97:135–87.

9. Manolagas SC, O'Brien CA, Almeida M. The role of estrogen and androgen receptors in bone health and disease. Nat Rev Endocrinol. 2003;9:699–712.

10. Kostenui S, Bellido T, Plotkin L, O'Brien CA, Bodenner DL, Han L, et al. Non-genomic, sex-specific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104:719–30.

11. Kang HY, Cho CL, Huang KL, Wang JC, Hu YC, Lin HK, et al. Nongenomic androgen activation of phosphatidylinositol 3-kinase/Akt signaling pathway in MCT3-E1 osteoblasts. J Bone Miner Res. 2004;19:1181–90.

12. Sobel V, Schwartz B, Zhu YS, Cordero JJ, Imperato-McGinley J. Bone mineral density in the complete androgen insensitivity and Salpha-reductase-2 deficiency syndromes. J Clin Endocrinol Metab. 2006;91:2017–23.

13. Seeman E. Periosteal bone formation–a neglected determinant of bone strength. N Engl J Med. 2003;349:320–3.

14. Duan Y, Turner CH, Kim BT, Seeman E. Sexual dimorphism in vertebral fragility is more the result of gender differences in age-related bone gain than bone loss. J Bone Miner Res. 2001;16:2267–75.

15. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761–7.

16. Seeman E. Clinical review 137: sexual dimorphism in skeletal size, density, and strength. J Clin Endocrinol Metab. 2001;86:4576–84.

17. Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kurnin MM, Rockwood AL, et al. Endogenous sex hormones and incident fracture risk in older men: the Duke Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168:47–54.

18. Mellstrom D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, Mallmin H, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MROS Sweden. J Bone Miner Res. 2006;21:529–35.

19. Golds G, Houdek D, Arason T. Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health. Int J Androl. 2017;40:621–9.

20. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone and androgens on murine cortical bone do not require AR or ERalpha signaling in stromal cells. Stem Cell Res. 2013;11:938.

21. Wang A, Obertova Z, Brown C, Karunasinghe N, Bishop K, Ferguson L, et al. Risk of fracture in men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897–805.

22. Kang HY, Shyr CR, Huang CK, Tsai MY, Orimo H, Lin PC, et al. Altered TNSALP with nonmetastatic prostate cancer. J Bone Miner Res. 2012;27:2535.

23. Almeida M, Laurent MR, Dubois V, Claessens F, O'Brien CA, Bouillon R, et al. Androgen receptor (AR) in osteocytes is important for the maintenance of male bone mass and androgens on murine cortical bone do not require AR or ERalpha signaling in stromal cells. Stem Cell Res. 2013;11:938.

24. Vanderschueren D, Venken K, Bouillon R, Boonen S. Clinical review: sex steroids and the periosteum–reviewing the roles of androgens and estrogens in periosteal expansion. J Clin Endocrinol Metab. 2006;91:378–82.

25. Cheng BH, Chu TM, Chang C, Kang HY, Huang KE. Testosterone delivered with a scaffold is as effective as bone morphogenetic protein-2 in promoting the repair of critical-size segmental defect of femoral bone in mice. PloS One. 2013;8:e70234.

26. Gelse K, Poschl E, Aigner T. Collagens-structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003;55:1531–46.

27. Kamata T, Takada Y. Direct binding of collagen to the I domain of integrin alpha 2 beta 1 (VLA-2, CD49b/CD29) in a divalent cation-independent manner. J Biol Chem. 1994;269:26006–10.

28. Kem A, Briesewitz R, Bank I, Macartono EE. The role of the I domain in ligand binding of the human integrin alpha 1 beta 1. J Biol Chem. 1994;269:28181–6.

29. Gronthos S, Stewart K, Graves SE, Hay S, Simmons PJ. Integrin expression and phosphate regulation contribute to reduced mineralization in mice lacking androgen receptor. Mol Cell Biol. 2008;28:7354–67.

30. Chiang C, Chiu M, Moore AJ, Anderson PH, Ghasem-Zadeh A, McManus JF, et al. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J Bone Miner Res. 2009;24:621–31.

31. Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure and function in periosteum and bone. Cell Death and Disease. 2017;8:e2973.

32. Lu X, Li W, Fukumoto S, Yamada Y, Evans CA, Diekwisch T, et al. The ameloblastin domain of ameloblastin regulates osteoclast formation. J Bone Miner Res. 2016;32:54:113–26.

33. Zeltz C, Gullberg D. The integrin-collagen-connection–a glue for tissue repair? J Cell Sci. 2016;129:653–64.

34. Ekholm E, Hankenson KD, Uusitalo H, Hiltunen A, Gardner H, Heino J, et al. Diminished callus size and cartilage synthesis in alpha 1 beta 1 integrin-deficient mice during bone fracture healing. Am J Pathol. 2002;160:1779–85.

35. Marie PJ, Hay E, Saidak Z. Integrin and cadherin signaling in bone: role and potential therapeutic targets. Trends Endocrinol Metab. 2014;25:567–75.

36. Lee SH, Lee YS, Han HJ. Role of hypoxia-induced fibronectin-integrin beta1 expression in hypoxia-driven embryonic stem cell proliferation and migration: Involvement of PI3K/Akt and FAK. J Cell Physiol. 2011;226:484–93.

37. Castoria G, D’Amato L, Ciocciola A, Giovannelli P, Giraldi T, Sepe L, et al. Androgen-induced cell migration: role of androgen receptor/afamin A association. PloS One. 2011;6:e17218.

38. Gonzalez-Gil AB, Lamo-Espinosa JM, Muinos-Lopez E, Ripalda-Gemborov P, Abizaid G, Vales-Fernandez J, et al. Periostium-derived mesenchymal progenitor cells in engineered implants promote fracture healing in a critical-size defect rat model. J Tissue Eng Regenerative Med. 2019;13:742–52.

39. Gesicki M, Tibba J, Nguyen C, Belf R, Reger J, Huberland M, et al. Testosterone is a potent accelerator of fracture healing: early structural reconstruction and improved biomechanical stability. Osteostimulation Trauma Care. 2003;11:3–5.

40. Tarsiøy E, Janosy K. Kosztura L. Effect of testosterone on fracture healing in hypophysectomized rats. Acta Histochemica. 1979;65:25–33.

41. Venken K, De Gendt K, Boonen S, Ophoff J, Bouillon R, Swinnen JV, et al. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model. J Bone Miner Res. 2006;21:576–85.

42. Vandervueren D, Venken K, Ophoff J, Bouillon R, Boonen S. Clinical review: sex steroids and the periosteum–reviewing the roles of androgens and estrogens in periosteal expansion. J Clin Endocrinol Metab. 2006;91:378–82.
58. Horikiri Y, Shimo T, Kurio N, Okui T, Matsumoto K, Iwamoto M, et al. Sonic hedgehog regulates osteoblast function by focal adhesion kinase signaling in the process of fracture healing. PLoS One. 2013;8:e76785.
59. Liao X, Lu S, Zhuo Y, Winter C, Xu W, Wang Y. Visualization of Src and FAK activity during the differentiation process from HMSCs to osteoblasts. PLoS One. 2012;7:e42709.
60. Hu J, Liao H, Ma Z, Chen H, Huang Z, Zhang Y, et al. Focal adhesion kinase signaling mediated the enhancement of osteogenesis of human mesenchymal stem cells induced by extracorporeal shockwave. Sci Rep. 2016;6:20875.
61. Kim JB, Leucht P, Luppen CA, Park YJ, Beggi HE, Damsky CH, et al. Reconciling the roles of FAK in osteoblast differentiation, osteoclast remodeling, and bone regeneration. Bone. 2007;41:38–49.
62. Leucht P, Kim JB, Currey JA, Brunski J, Helms JA. FAK-Mediated mechanotransduction in skeletal regeneration. PLoS One. 2007;2:e390.
63. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, et al. Cloning and characterization of androgen receptor coactivator, ARASS, in human prostate. J Biol Chem. 1999;274:8316–21.
64. Leach DA, Need EF, Trotta AP, Grubisha MJ, DeFranco DB, Buchanan G. Hic-5 influences genomic and non-genomic actions of the androgen receptor in prostate myofibroblasts. Mol Cell Endocrinol. 2014;384:185–99.
65. Stanovici J, Le Nail LR, Brennan MA, Vidal L, Trichet V, Rosset P, et al. Bone regeneration strategies with bone marrow stromal cells in orthopaedic surgery. Curr Res Transl Med. 2016;64:83–90.
66. Roberts SJ, van Gastel N, Carmeliet G, Luyten FP. Uncovering the periosteum for skeletal regeneration: the stem cell that lies beneath. Bone. 2015;70:10–18.
67. Stewart S, Bryant SJ, Ahn J, Hankenson KD. Bone regeneration. In: Atala A, Allickson Roberts SJ, van Gastel N, Carmeliet G, Luyten FP. Uncovering the periosteum for skeletal regeneration: the stem cell that lies beneath. Bone. 2015;70:10–18.
68. Ma T, Gutnick J, Olivo M, Chang HC, Mizokami A, et al. Cloning and characterization of androgen receptor coactivator, ARASS, in human prostate. J Biol Chem. 1999;274:8316–21.
69. Srouji S, Blumenfeld I, Rachmiel A, Livne E. Bone defect repair in rat tibia by TGF-
70. Neagu TP, Tiglis M, Cocolos I, Jecan CR. The relationship between periosteum and bone healing. Bone. 2008;43:1075–83.
71. Meyer RA, Meyer MH, Phieffer LS, Banks DM. Delayed union of femoral fractures in older rats: decreased gene expression. BMC Musculoskelet Disord. 2001;2:2.
72. Chu TM, Warden SJ, Turner CH, Stewart RL. Segmental bone regeneration using a load-bearing biodegradable carrier of bone morphogenetic protein-2. Biomaterials. 2007;28:459–67.
73. Zhang X, Schwartz EM, Young DA, Putaz JE, Rosier RN, O’Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002;109:1405–15.
74. Veh PM, Wanderer SJ, Turner CH, Stewart RL. Segmental bone regeneration using a load-bearing biodegradable carrier of bone morphogenetic protein-2. Biomat erials. 2007;28:459–67.
75. Zhang X, Schwartz EM, Young DA, Putaz JE, Rosier RN, O’Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002;109:1405–15.
76. Xie C, Ming X, Wang Q, Schwartz EM, Goldberg RE, O’Keefe RJ, et al. COX-2 from the injury milieu is critical for the initiation of periosteal progenitor cell mediated bone healing. Bone. 2008;43:1075–83.
77. Horikiri Y, Shimo T, Kurio N, Okui T, Matsumoto K, Iwamoto M, et al. Sonic hedgehog regulates osteoblast function by focal adhesion kinase signaling in the process of fracture healing. PLoS One. 2013;8:e76785.
78. Liao X, Lu S, Zhuo Y, Winter C, Xu W, Wang Y. Visualization of Src and FAK activity during the differentiation process from HMSCs to osteoblasts. PLoS One. 2012;7:e42709.
79. Hu J, Liao H, Ma Z, Chen H, Huang Z, Zhang Y, et al. Focal adhesion kinase signaling mediated the enhancement of osteogenesis of human mesenchymal stem cells induced by extracorporeal shockwave. Sci Rep. 2016;6:20875.
80. Kim JB, Leucht P, Luppen CA, Park YJ, Beggi HE, Damsky CH, et al. Reconciling the roles of FAK in osteoblast differentiation, osteoclast remodeling, and bone regeneration. Bone. 2007;41:38–49.
81. Leucht P, Kim JB, Currey JA, Brunski J, Helms JA. FAK-Mediated mechanotransduction in skeletal regeneration. PLoS One. 2007;2:e390.
82. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, et al. Cloning and characterization of androgen receptor coactivator, ARASS, in human prostate. J Biol Chem. 1999;274:8316–21.
83. Ma T, Gutnick J, Olivo M, Chang HC, Mizokami A, et al. Cloning and characterization of androgen receptor coactivator, ARASS, in human prostate. J Biol Chem. 1999;274:8316–21.
84. Srouji S, Blumenfeld I, Rachmiel A, Livne E. Bone defect repair in rat tibia by TGF-
85. Neagu TP, Tiglis M, Cocolos I, Jecan CR. The relationship between periosteum and bone healing. Bone. 2008;43:1075–83.